Cytovance Biologics hires vp of sales and business development

Valerie McDonnell joins from Althea

Cytovance Biologics, a biopharmaceutical contract manufacturing company specialising in the production of therapeutic proteins and antibodies from mammalian cell culture, has appointed Valerie McDonnell as vice president of sales and business development.

McDonnell has more than 22 years’ experience in the biotech industry. Prior to joining Cytovance she was vice president of sales at Althea.

Before joining Althea she was a study director at BioReliance where she was responsible for client programmes in the Molecular Biology Department. She also worked at The Institute for Genomic Research (TIGR) and participated in the Haemophilus influenzae sequencing programme.

You may also like

Manufacturing

Avantor and Cytovance collaborate on plasmid DNA supply

The collaboration extends Avantor’s offering of critical materials for vaccines and therapeutics focused on cell and gene therapy
Manufacturing

Cytovance Biologics to expand microbial manufacturing

Has acquired 100L and 1,000L fermenters
Manufacturing

Cytovance Biologics to expand production capabilities in 2013

Installs a 1,000L SUB bioreactor, 5,000L stainless steel bioreactor and fill/finish line
Manufacturing

Cytovance adds 1,000L bioreactor to mammalian facility

Will complement existing manufacturing process trains in Oklahoma City
Manufacturing

Roquette opens pharmaceutical innovation centre in Brazil

The Health & Pharma Solutions facility in São Paolo offers state-of-the-art laboratories for customers, with the Northeast Center for Strategic Technologies partnering with Roquette to empower young women to pursue careers in science through the Futuras Cientistas programme at the facility
Manufacturing

RHEOFREED: A game-changing innovation in lyophilization technology

Dec Group announces its partnership with Kobelco Eco Solutions, Japan, and presents RHEOFREED®, a revolutionary mixer-type freeze dryer at CPHI Frankfurt 2025
Manufacturing

Samsung Bioepis and Phrontline join forces to advance best-in-class antibody-drug conjugate therapeutics for solid tumours

The pair will co-develop two investigational ADC assets directed against targets expressed in a broad range of cancers, adding a new class of bispecific and dual-payload ADC therapeutics to Samsung Bioepis' oncology portfolio
Subscribe now